CN1299769C

CN1299769C - Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof

Info

Publication number: CN1299769C
Application number: CNB2005100049911A
Authority: CN
Inventors: 赵清正; 千新来
Original assignee: Cancer Hospital and Institute of CAMS and PUMC
Current assignee: Beijing Yunhe Jinfan Technology Co ltd
Priority date: 2005-01-31
Filing date: 2005-01-31
Publication date: 2007-02-14
Anticipated expiration: 2025-01-31
Also published as: CN1679930A

Abstract

The present invention relates to a fusion gene which is obtained by fusing a modified human papillomavirus 16 (HPV-16) E6/E7 gene and a reformed branched tubercle bacillus heat shock protein 70 (TBhsp 70) gene. The present invention also relates to a preparation method of the fusion gene, the construction and an expression carrier of a high-efficiency expression carrier containing the fusion gene, a recombinant protein vaccine obtained by the fusion gene, and the application of the fusion gene and the recombinant protein vaccine to the preparation of medicine for preventing and treating tumors relevant to HPVs. The recombinant protein vaccine of the present invention has strong immune competence and the function of resisting tumors by the verification of experiments. Moreover, the present invention doesn't need to be used by combining with other immune assisting agents.

Description

Human papillomavirus and heat shock protein recombinant protein vaccine and uses thereof

Technical field

The present invention relates to a kind of human papillomavirus and heat shock protein fusion gene, its expression vector and recombinant protein vaccine, relate in particular to HPV 16 (HPV-16) E6/E7 of modification and branch tubercule bacillus heat shock protein 70 (TBhsp70) fusion gene of transformation, the preparation method of this fusion gene, the structure and the expression vector that contain the efficient expression vector of this fusion gene, the fusion rotein that utilizes this fusion gene to obtain, and described fusion gene and the application of fusion rotein in preparation control human papillomavirus's relevant disease and tumour medicine.

Background technology

Malignant tumor is commonly encountered diseases, the frequently-occurring disease of serious harm human health.Present three big conventional treatments in the oncotherapy: though operation, radiation and chemotherapy have had certain development, but, excision is the topical therapeutic means, and malignant tumor is infiltrative growth, and easily pass through blood vessel and/or lymphatic vessel generation metastasis, thereby be difficult to reach the purpose of removing cancerous cell fully for advanced malignant tumor patient surgery alone; Radiotherapy also is the treatment means based on the part, has the defective in the operative treatment equally, and many malignant tumor are to radiotherapy and insensitive; Chemotherapy is the whole body therapeutic means, but it is faced with drug resistance and the big shortcoming of toxic and side effects.Therefore, the new treatment measure of research malignant tumor and to develop new control bio-pharmaceutical be one of important topic of various countries oncology worker concern.

Massive epidemiology and clinical research are verified both at home and abroad: HPV, particularly the HPV16 type is closely related with the generation of malignant tumor such as cervical cancer, the esophageal carcinoma, pulmonary carcinoma, head-neck malignant tumor, stomach carcinoma of gastric cardia, skin carcinoma, breast carcinoma, bladder cancer, ovarian cancer, carcinoma of prostate, carcinoma of penis, anus cancer and colorectal cancer.The etiology of HPV and cervical cancer relation approved widely, the HPV16 type be the main diseases viral disease that causes cervical cancer because of.One relates to Shanghai, Guangzhou, Beijing, Sichuan and Hong Kong 5 provinces and cities and geographic multicenter study (Int.J.Cancer, 100:327-331,2002) data shows: the cervical cancer patient at China 78.7-87.7% has HPV to infect, and wherein 61.7-91.8% is that HPV16 infects.Mechanism of carcinogenesis to HPV studies show that: behind the HPV host cells infected, two oncogene E6 and E7 stable integration are in the host cell gene group DNA and continuous expression, and this is HPV inducing cell generation vicious transformation and keeps malignant phenotype's key.Therefore, E6 and E7 become the focus that people study canceration mechanism and control usefulness new biological product.Research also shows: the main glutelin L1 with HPV infects effectively prevention HPV as vaccine, but the infected is not had prevention and therapeutical effect; This vaccine production difficulty is its another shortcoming; because the preparation of VLP (virus-like particle) is consuming time, consumption material, trivial operations, need through 3 times super centrifugal and yield is too low (only be last super when centrifugal Tot Prot 2/10000ths to 5/10000ths), thereby produce in batches to scale and to have brought a lot of difficulties.Studies show that in recent years, use the E6 or the E7 albumen of prokaryotic expression certain prevention effect to be arranged separately as therapeutic vaccine, researcher once imagined E6/E7 fusion rotein that use do not transform as vaccine in the hope of improving prevention effect, but do not have using value owing to E6 itself or E6/E7 expressing fusion protein level are too low.And owing to be that its safety is subjected to people's query without the wild type oncoprotein of transforming.The virus that contains E6 and E7 gene, or be the dna vaccination of carrier with the plasmid, owing to may be incorporated in the cellular genome, also there is safety issue.As vaccine, cost is high and limited by MHC with synthetic polypeptide, and the scope of application is limited.

A large amount of studies show that: for the disease of serious harm human healths such as tumor, immunization therapy is a kind of effective method.Though the multiple highly purified new generation vaccine of developing at present has good specificity and hypotoxicity, need be used with adjuvant efficiently.Expanded the space of immunization therapy for the further investigation of adjuvant.But, even on the one hand because different adjuvants also can produce different effects to same antigen; On the other hand, because for body, adjuvant is an exogenous material, and it is low that specificity is replied in the inductive natural immunity of adjuvant, therefore, may cause a series of toxicity (comprise local inflammation, be difficult to tuberosity, cyst, oncogenic function, teratogenesis and the cross-immune reaction etc. that disappear for a long time).Therefore, the application of adjuvant has effectiveness, safety, selectivity, controllability and the problems such as other theory, technology and manufacturing that must consider.As: though uniting use with common vaccine, classical aluminium adjuvant obtaining secular practice confirmation aspect raising antibody horizontal and the safety, but it is not then having effect to engineered protein or polypeptide aspect inducing cell immunocompetence, add and its mechanism of action is understood less, make it to be difficult to satisfy the needs of new generation vaccine; For another example, although incomplete Freund (IFA) all proves one of the most successful adjuvant at animal and human's apoplexy due to endogenous wind, but its possible side effect people still have worry, as: use the local normal tuberosity that forms, even liquefaction forms cyst, report is arranged, and it has oncogenic function (BullWHO, 1969 in male Swiss mice; 41:617-621), but in BALB/c and C57BL/6 mice tumorigenesis not, thereby still have worry with regard to safety issue.At last, although developed multiple novel adjuvant at present, safety and the mechanism of action etc. still remains to be furtherd investigate.

A large amount of research is verified: heat shock protein has strong immunogenicity, as: 1. can induce strong antitumor or antiviral immunity from tumor or the isolating hsps complex of virus infected cell; 2. during mycobacterial infections, what high frequency was arranged is the people CD4 of target spot with hsp70 and 60 etc. ⁺The T cell occurs; 3. a plurality of Mus of hsps and people's B cell and t cell epitope are identified, and can be mammalian cell identification.This impels researcher to utilize this specific character development infectious disease vaccine of hsps and the strategy of immunotherapy of tumors, also provides foundation for it is used as no adjuvant carrier simultaneously.Researcher with hsp70 and the little peptide of malaria (NANP) 40, HIV-1p24, ovalbumin etc. covalently bound after, do not having under other adjuvant condition, having excited with these peptides or engineered protein is the specificity humoral and the cell immune response of target spot.Specific C D8 ⁺Inducing in antineoplastic immune of ctl response plays an important role, and possible mechanism has: 1. contain t cell epitope with the covalently bound destination protein of hsp70 itself, owing to added the t cell epitope of hsp70, thereby immunogenicity is stronger; 2. contain multiple known or still unknown epitope with the covalently bound destination protein of hsp70, can give full play to its effect; 3. the hsp70 fusion rotein can provide special CD4 of the same clan by activating the full-time antigen presenting cell of sharing (APCs) ⁺Helper T lymphocyte activates the special CD8 of destination protein ⁺CTL; 4. hsp70 has chaperone function, can help protein folding, can promote covalently bound with it albumen ubiquitinization and can be stimulated full-time APCs to raise the expression of MHC I and II molecule and costimulatory molecules in vivo and in vitro by the APCs of sole duty picked-up, hsp70 fusion rotein by receptor mediated endocytosis by well processing, TBhsp70 fusion rotein, this not only helps destination protein and enters full-time APCs and submission to corresponding cell subunit, and helps the formation of MHC-peptide complexes and submission to cell surface; 5. research in recent years (J.Exp.Med., 191:403-408,2000) shows: the hsp70 fusion rotein is induced the CD8 of destination protein ⁺Ctl response does not only need adjuvant, does not need its chaperone function yet, has also overcome the restriction of MHC, does not also need CD4 ⁺The help of T cell.In sum, the treatment of TBhsp70 fusion protein immunization can be induced CD8 ⁺Ctl response does not need adjuvant, does not need CD4 ⁺The help of T cell is not limited by MHC, does not need viral vector, has avoided the potential safety issue of DNA sequence of dna vaccination, and easily a large amount of preparation, safety are good.Adding that malignant tumor patient autoimmunity is low, down-regulated expressions such as cancerous cell MHC molecule and costimulatory molecules, HIV infect and cause CD4 ⁺The remarkable destruction of T cell etc., these all make the hsp70 fusion rotein have remarkable advantages on the immunization therapy strategy of development antitumor, anti-HIV and other infectious disease.

Summary of the invention

One of the object of the invention is to overcome the deficiencies in the prior art, and a kind of recombinant protein vaccine that can effectively treat the tumor relevant with HPV and not need immunological adjuvant is provided.

One of the object of the invention realizes by following technological approaches:

A kind of recombinant protein vaccine that can effectively treat the tumor relevant and not need immunological adjuvant of the present invention with HPV, it be by the aminoacid sequence of ATP-binding site 161-370 amino acids sequence, human papillomavirus E6 albumen 1-120 position in the hsp70 albumen and E7 albumen altogether 98 aminoacid sequences be formed by connecting, wherein the leucine with the 50th in E6 albumen is modified to glycine, cysteine that E7 is proteic the 24th and 26 glutamic acid be modified to glycine respectively; Wherein human papillomavirus E6 albumen is positioned at the aminoterminal of this recombiant protein, and hsp70 albumen is positioned at the c-terminus of this recombiant protein.

Recombinant protein vaccine of the present invention preferably has the aminoacid sequence shown in the SEQ ID NO:2 in the sequence table;

Recombinant protein vaccine of the present invention has stronger immunocompetence and anti-tumor function, and does not need immunological adjuvant.

Two of purpose of the present invention provides a kind of fusion gene of the above-mentioned recombinant protein vaccine of encoding.

Two of purpose of the present invention realizes by following technological approaches:

A kind of fusion gene of the present invention, by forming through changing structure and the human papillomavirus E6/E7 gene of modifying and mycobacterium heat shock protein 70 gene fusion of transformation, this fusion gene comprises the nucleotide sequence of the part (161-370 aminoacid) of hsp70 gene code ATP-binding site; The amino acid whose nucleotide sequence of 1-120 position comprises complete B-epi-position (1-23aa) and 2 CTL epi-position (29-38aa among the E6 before the E6 gene code of HPV; 52-61aa); The E7 gene code of HPV is 98 amino acid whose nucleotide sequences altogether, comprise 4 CTL epi-position (7-15aa among the E7; 11-20aa; 49-57aa and 79-87aa), Th epi-position (48-54aa) and 3 B epi-position (1-18aa; 25-37aa and 43-60aa).In addition, the codon of the 24th cysteine of coding of the 50th lysine of the coding of E6 gene, E7 gene and the 26th glutamic acid of coding of E7 gene, adopt the rite-directed mutagenesis method to carry out gene mutation, to remove its effect, increase the safety of expressed recombinant protein vaccine in conjunction with antioncogene.

The characteristics of fusion gene of the present invention are can efficiently express the purpose fusion rotein and have stronger immunocompetence and anti-cancer function in the host.

This fusion gene prepares by following steps:

(A) obtain TBhsp70, E6 and E7 gene;

(B) codon with the 26th glutamic acid of coding of the 24th cysteine of coding of the 50th lysine of coding of E6 gene, E7 gene and E7 gene carries out rite-directed mutagenesis;

(C) with the amino acid whose nucleotide sequence of 1-120 position before the nucleotide sequence of the part (161-370 aminoacid) of TBhsp70 gene code ATP-binding site, the E6 gene code and E7 gene code altogether 98 amino acid whose nucleotide sequences merge.

Another purpose of the present invention provides expression vector that contains above-mentioned fusion gene and the host cell that contains this expression vector.

A further object of the invention provides above-mentioned recombinant protein vaccine and the application of fusion gene in medical science.

Further object of the present invention provides above-mentioned recombinant protein vaccine and treats and/or prevents application in the HPV related neoplasms medicine in preparation.

Human papillomavirus E6/E7 of the present invention and mycobacterium heat shock protein 70 fusion genes can be used for preparing safety, effectively, can efficiently express, the protein vaccines that are used to prevent and treat HPV related neoplasms such as cervical cancer etc. of a large amount of preparations easily, this protein vaccine inducing specific CD8 ⁺Ctl response and without any need for adjuvant.Because malignant tumor patient autoimmunity is low, down-regulated expressions such as cancerous cell MHC molecule and costimulatory molecules, therefore, recombinant protein vaccine of the present invention has remarkable advantages on the anti-HPV related neoplasms of development and other infectious disease immunization therapy strategy.

Description of drawings

Fig. 1 SDS-PAGE analyzes the evaluation (Western blot) of mE6 Δ/mE7/hsp70 Δ Expression of Fusion Protein, purification and fusion rotein

M: molecular weight of albumen standard; 1: the fusion rotein of purification; The empty bacteria-induction of 2:BL21 (DE3) 0 hour; 3,4: BL21 (DE3) bacteria-induction of commentaries on classics PET30a (+) empty carrier 0 hour, 4 hours; 5,6: BL21 (DE3) bacteria-induction of commentaries on classics PET30a (+)-mE6 Δ/mE7/TBhsp70 Δ recombiant plasmid 0 hour, 4 hours; 7,8:E6, E7 Western blot identify

Fig. 2 does not have the attack of adjuvant reorganization mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine prevention TC-1 cell and attacks

-◆-PBS group

-■-hsp70 Δ group

The mE6 of-▲-Δ/mE7 group

-■-mE6 Δ/mE7/hsp70 Δ group

Fig. 3 does not have the attack (tumor average volume of inoculation TC-1 cell after 43 days) of adjuvant reorganization mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine prevention TC-1 tumor cell

Fig. 4 does not have the growth of adjuvant reorganization mE6 Δ/entity tumor that the inhibition of mE7/hsp70 Δ amalgamation protein vaccine has formed

-◆-PBS group

-■-mE6 Δ/mE7/hsp70 Δ group

Further describe beneficial effect of the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit protection scope of the present invention.

The specific embodiment

[embodiment]

The structure of one, the acquisition of mycobacterium heat shock protein 70 genes, human papillomavirus E6 and E7 gene, transformation and mE6 Δ/mE7/hsp70 Δ fusion gene and reorganization prokaryotic expression plasmid vector

1. the acquisition and the transformation of mycobacterium heat shock protein 70 genes

Cultivate the branch tubercule bacillus, extract genomic DNA, nucleotide sequence (called after TBhsp70 Δ) with the part (161-370 aminoacid) of PCR method amplification hsp70 gene code ATP-binding site, the sequence two ends are introduced BamH I and Xho I restriction enzyme site respectively, behind sequence analysis, consistent with the GeneBank comparative sequences.

2. the acquisition of human papillomavirus E6 and E7 gene

Extract genomic DNA from the male cervical cancer patient tumors of HPV16 tissue, with PCR method increase respectively E6 and E7 gene, through sequence analysis, the E7 gene DNA sequence is consistent with external report, 98 aminoacid of encoding altogether; The E6 gene DNA sequence is except T → C of the 259th, and all the other are in consistent with external report, 158 aminoacid of encoding altogether.This point mutation causes amino acids coding to become arginine (the 87th amino acids in the E6 albumen) by cysteine.This point mutation is positioned at outside the known epi-position of E6, so its immunogenicity is not had influence.

3. the rite-directed mutagenesis of human papillomavirus E6 and E7 gene

Because the 50th leucine in the albumen of E6 coded by said gene causes the critical sites of antioncogene p53 inactivation, the 24th cysteine in the albumen of E7 coded by said gene and 26 glutamic acid are the critical sites of study of tumor suppressor genes Rb inactivation, so by the method for rite-directed mutagenesis glycine is changed in these three sites.To remove the activity of its combination and deactivation antioncogene, increase the safety of vaccine.E6 after the sudden change and E7 gene be called after mE6 and mE7 respectively.

4.mE6 the structure of Δ/mE7/TBhsp70 Δ fusion gene and reorganization prokaryotic expression plasmid vector

With above-mentioned mE6 is template with the increase nucleotide sequence of 1-120 amino acids before its coding of PCR method, and introduces Nco I restriction enzyme site at its 5 ' end.Divide the elongated segment method progressively to add E7 gene code 98 amino acid whose nucleotide sequences altogether with PCR then, and add BamH I restriction enzyme site at its 3 ' end at 3 of mE6 Δ ' end.The fusion gene sequence that is obtained through the sequence analysis proof is correct, has kept the mutational site.Called after mE6 Δ/mE7.Then with Nco I and BamH II difference double digestion PET30a (+) plasmid and mE6 Δ/mE7 fusion gene, after the recovery, spend the night with 12 ℃ of connections of T4DNA ligase, transform DH5 α competence antibacterial, screening positive clone on ampicillin LB agar plate, the amplification of picking list bacterium colony is also extracted recombinant plasmid vector.Called after PET30a (+)-mE6 Δ/mE7.With BamH I and Xho I difference double digestion hsp70 Δ and PET30a (+)-mE6 Δ/mE7, to reclaim, recombiant plasmid is also extracted in the same connection, conversion, screening, the amplification of picking list bacterium colony.Called after PET30a (+)-mE6 Δ/mE7/TBhsp70 Δ.So far, mE6 Δ/mE7/TBhsp70 Δ fusion gene (sequencing result is seen SEQ ID NO:1) and reorganization prokaryotic expression plasmid vector thereof have successfully been made up.The recombinant plasmid vector called after PET30a (+) that only the contains the TBhsp70 Δ-TBhsp70 Δ of Gou Jianing simultaneously.

Two, the structure of efficient expression engineering and Expression of Fusion Protein are identified

With the reorganization prokaryotic expression plasmid transformed into escherichia coli BL21 (DE3) (Novagen company) of above-mentioned structure, and 80 single bacterium colonies of picking are observed expression at random.37 ℃ are shaken bacterium to OD ₆₀₀During for 0.5-0.6, express with the IPTG induced protein of 1mM (final concentration), SDS-PAGE electrophoresis (12.5%) is walked in sampling after 4 hours, then with examining the dyeing of Ma Shi light blue, the fusion rotein band (Fig. 1) of the destaining solution decolouring visible about 52KD in back.Use the monoclonal antibody (Santa Cruz company) of anti-his-tag, HPV16E6 and E7 respectively expressed proteins to be carried out Western blot Analysis and Identification (Fig. 1) then, prove that this albumen is the purpose fusion rotein, and molecular weight fulfills the expectation.The reuse similarity condition ferments, the sample of getting different time points (1-5 hour) is through the SDS-PAGE electrophoretic analysis, BSA with concentration known is that reference standard carries out electrophoresis simultaneously simultaneously, dyed and the decolouring after, carry out photodensitometry with the automated imaging scanner, when fermentation culture after 4 hours, destination protein reaches saturation, accounts for about 30% of thalline total amount.Experimental results show that further this fusion rotein exists with the form of occlusion body.

Three, the purification of protein product and dialysis renaturation (antibacterial of cultivating with 100ml is an example)

1. induce and harvesting

Cultivate efficient expression engineering to OD for 37 ℃ ₆₀₀During for 0.5-0.6, express centrifugal cell harvesting after 4 hours with the IPTG induced protein of 1mM (final concentration), with lysis buffer (150mM NaCL, NP401%, deoxycholic acid 0.5%, SDS 0.1%) re-suspended cell and further ultrasonication cell in ice bath.

2. the preparation of occlusion body and dissolving

12000g, 4 ℃ are centrifugal, and 20 minutes, supernatant discarded was with 10ml degeneration extraction/lavation buffer solution (50mMNa ₃PO ₄, 6M guanidine hydrochloride, 300mM NaCL) and abundant on ice dissolution precipitation; 12000g, 4 ℃ centrifugal, 20 minutes, preserves supernatant in 4 ℃ of refrigerators.

3. balance resin and upload fusion rotein

Getting the 6ml affinity chromatography medium is TALON ^TMMetal affinity chromatograph resin storage liquid, 3600g, 4 ℃ are centrifugal, 5 minutes; With 10ml degeneration extraction/lavation buffer solution balance 2 times, will contain the solution and the mixed with resin of occlusion body, wash 2 times with 10ml degeneration extraction/lavation buffer solution after, in the chromatographic column of carefully packing into.

4. wash foreign protein and eluting fusion rotein

With 20ml degeneration extraction/lavation buffer solution washing chromatographic column, flow velocity: 0.5ml/ minute; With 20ml imidazoles elution buffer (45mM Na ₃PO ₄, 5.4M guanidine hydrochloride, 270mM NaCL, 150ml imidazoles) and the eluting fusion rotein, flow velocity: 0.3ml/ minute, substep was collected, every pipe 0.5ml.

5. dialysis renaturation and albumen concentrate

With the fusion rotein solution of the eluting bag filter of packing into, the PBS of the guanidine hydrochloride that contains variable concentrations to be dialysed, the concentration that reduces guanidine hydrochloride step by step is until the PBS of hydrochloric guanidine is not dialysed.After finishing, dialysis concentrates fusion rotein to the concentration that needs with PEG20000.

6. fusion rotein purity is identified and is quantitative

Get dialysis renaturation and spissated protein solution 5-10ul and carry out the proteic purity of SDS-PAGE electrophoretic analysis (Fig. 1) (＞95%), press the Bradford method and measure protein concentration.

In order to last method repetition test, the fusion rotein response rate is at 50-60%.Use the 1L fermentation liquid, amplify above-mentioned steps in proportion, finally can get product (purity＞95%) 150-180mg.

[test example 1] amalgamation protein vaccine prophylaxis of tumours effect test of the present invention

C57BL/6 female mice (available from Chinese Academy of Medical Sciences's Experimental Animal Center, body weight 18-20 gram) is divided into four groups at random: PBS group, TBhsp70 Δ group, mE6 Δ/mE7 group and mE6 Δ/mE7/TBhsp70 Δ group, 10 every group.Use PBS (0.2ml), TBhsp70 Δ (containing the proteic PBS0.2ml of 1.5nM), mE6 Δ/mE7 (containing the proteic PBS0.2ml of 1.5nM), mE6/mE7/TBhsp70 Δ (0.2mlPBS that contains the 1.5nM fusion rotein) percutaneous to inject (groin place) down respectively and carry out immunity, after immune 2 weeks for the first time, the same booster immunization once, booster immunization is after 2 weeks, with 6 * 10 ⁴The TC-1 tumor cell attacks in subcutaneous right rib veutro that (TC-1 is the mouse tumor cell that is transformed with HPV16 type E6 and E7 gene and activated Ras oncogene, be so kind as to give by doctor Wu of U.S. Johns Hopkins university), the observation experiment animal goes out the tumor time, measures the tumor size and calculates gross tumor volume: gross tumor volume=major diameter * minor axis ²/ 2.The result shows: mE6 Δ/mE7/hsp70 Δ group goes out evening tumor time, and 7 are finished (43 days) to experiment and do not see tumor growth, though 3 grow tumor, wherein 2 disappear again fully, promptly finish only to have 1 mice with tumor to experiment.And 3 all laboratory animals of matched group all have tumor growth (Fig. 2).PBS group, hsp70 Δ group, mE6 Δ/mE7 group and mE6 Δ/mE7/hsp70 Δ group tumor average volume are respectively when testing the 43rd day: 3835.2 ± 172.7mm ³, 3685.3 ± 158.6mm ³, 3135.3 ± 181.7mm ³And 10mm ³(Fig. 3).Tested the 51st day, and mE6 Δ/9 no tumor Mus of mE7/hsp70 Δ group were attacked with more heavy dose of TC-1 tumor cell again, the result shows: there are 2 mices that the tumor growth of one mistake property is arranged, but disappear fully again afterwards (Fig. 2).

Above presentation of results: after no adjuvant mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine immunity, can make the immunization experiment animal produce strong specificity antineoplastic immunity reaction, this immunoreation can be repelled the attack of cancerous cell, prevents the formation of tumor, thereby has preventive effect.The high-risk group who is used in the HPV16 infection prevents the generation of HPV related neoplasms.

[test example 2] amalgamation protein vaccine of the present invention suppresses growth of tumor effect test

In view of the prevention experimental result instruction book all can not produce specific anti tumor immune response with hsp70 Δ or mE6 Δ/mE7 laboratory animal, so group is established in research subsequently no longer separately.Laboratory animal, immunization method etc. are the same.Earlier 20 mices are inoculated the TC-1 tumor cell in subcutaneous right rib veutro, 1.3 * 105/, treat that tumor average volume reaches 5mm ³The time, random packet, 10/group, and carry out the immunity first time, booster immunization is once after 2 weeks.Observe tumor size and mice life span, calculate gross tumor volume by above-mentioned formula.The result shows: mE6 Δ/mE7/hsp70 Δ group tumor growth obviously is suppressed, and PBS group and mE6 Δ/mE7/hsp70 Δ group tumor average volume are respectively when testing the 35th day: 3508.4 ± 156.9mm ³With 408.5 ± 80.3mm ³(Fig. 4), PBS group and mE6 Δ/mE7/hsp70 Δ group mice with tumor mean survival time are respectively: 34.2 days and 80.8 days, wherein mE6 Δ/mE7/hsp70 Δ group had 2 animal tumors to disappear fully, obtained long term survival.

Above presentation of results: no adjuvant mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine immunity, can make the immunization experiment animal produce strong specificity antineoplastic immunity reaction, this immunoreation can obviously suppress the growth of the entity tumor that formed, thereby has therapeutical effect.Can be used for the treatment of HPV related neoplasms.

[test example 3] amalgamation protein vaccine of the present invention is to the prevention and the therapeutical effect of neoplasm metastasis

Laboratory animal and immunization method are with testing example 2, immunity earlier 2 times, 4 week back tail vein injection TC-1 tumor cells (2 * 10 ⁴/ only), inoculation TC-1 cell 5 week back is put to death mices and is observed lung transfer case (if naked eyes are not seen transfer with the whole embeddings of lung, transfer case under the serial section sight glass).The result shows: lung all takes place and shifts (7 visible metastasis of naked eyes wherein, 3 shift at the visible lung of microscopically) in 10 mices of PBS group; ME6 Δ/mE7/hsp70 Δ fusion rotein group has 2 as seen to shift at microscopically, under 8 naked eyes and the mirror all less than shifting (table 1).

Table 1

Group	Naked eyes shift	Mirror shifts down	Do not have and shift	The rate of transform (%)
Group	Naked eyes shift	Mirror shifts down	Do not have and shift	The rate of transform (%)	PBS group mE6 Δ/mE7/hsp70 Δ	7 0	3 2	0 8	100 20

After no adjuvant mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine immunity is described, can make the immunization experiment animal produce strong specificity antineoplastic immunity reaction, this immunoreation can prevent the transfer of tumor cell, thereby has the effect that prevention is shifted.Can be used for the transcellular prevention of HPV related neoplasms.

The tail vein injection TC-1 of elder generation tumor cell (2 * 10 ⁴/ only), random packet after 1 week, every group 10, treatment divides 2 groups, begin immunity (treating 1 group) after 1 week for the TC-1 cell for one group, another group is beginning immunity (treating 2 groups) for the TC-1 cell after 5 weeks, each group all 5 week of immunity the back put to death mices and observe the lung transfer case (if naked eyes are not seen transfer with the whole embeddings of lung, transfer case under the serial section sight glass.The result shows: lung all takes place and shifts (8 visible metastasis of naked eyes wherein, 2 shift at the visible lung of microscopically) in 10 mices of PBS group; Treating 1 group has 1 visible naked eyes to shift, and as seen 2 shifted at microscopically, all not transfers under 7 naked eyes and the mirror; Treating 2 groups has 2 visible naked eyes to shift, and as seen 3 shifted at microscopically, all not transfers (table 2) under 5 naked eyes and the mirror.

Table 2

Group	Naked eyes shift	Mirror shifts down	Do not have and shift	The rate of transform (%)
Group	Naked eyes shift	Mirror shifts down	Do not have and shift	The rate of transform (%)	PBS group mE6 Δ/mE7/hsp70 Δ (treating 1 group) mE6 Δ/mE7/hsp70 Δ (treating 2 groups)	8 1 2	2 2 3	0 7 5	100 30 50

After no adjuvant mE6 Δ/mE7/hsp70 Δ amalgamation protein vaccine immunity is described, can make the immunization experiment animal produce strong specificity antineoplastic immunity reaction, this immunoreation can suppress the growth of metastatic tumo(u)r, thereby neoplasm metastasis is had effect.Can be used for the transcellular treatment of HPV related neoplasms.

To sum up, advantage of the present invention be human papilloma virus E6/E7 and mycobacterium heat shock protein 70 fusions can be used for preparing safety, effectively, can efficiently express, the easy amalgamation protein vaccine that is used for prevention and treatment HPV related neoplasms (such as cervical carcinoma etc.) and shifts of a large amount of preparations, recombinant protein vaccine inducing specific CD8 of the present invention⁺Ctl response does not need adjuvant. Because malignant tumor patient autoimmunity is low, cancer cell MHC molecule and costimulatory molecules etc. are expressed downward modulation, add at present for protein vaccine, best adjuvant and the shortage of carrier have seriously perplexed the development of protein vaccine, therefore, recombinant protein vaccine of the present invention has obvious advantage at the anti-HPV related neoplasms of development and other infectious diseases Immunotherapy Strategy. Has undoubtedly important clinical value.

Sequence table

SEQUENCE LISTING

＜110〉Tumar Inst of Tumoor Hospital, Chinese Academy of Medical Sciences

＜120〉human papillomavirus and heat shock protein recombinant protein vaccine and uses thereof

<130>20050126

<160>2

<170>PatentIn version 3.3

<210>1

<211>1293

<212>DNA

<213>Homo sapiens

<400>1

atgcaccaaa agagaactgc aatgtttcag gacccacagg agcgacccag aaagttacca 60

cagttatgca cagagctgca aacaactata catgatataa tattagaatg tgtgtactgc 120

aagcaacagt tactgcgacg tgaggtaggt gactttgctt ttcgggattt atgcatagta 180

tatagagatg ggaatccata tgctgtatgt gataaatgtt taaagtttta ttctaaaatt 240

agtgagtata gacattatcg ttatagtttg tatggaacaa cattagaaca gcaatacaac 300

aaaccgttgt gtgatttgtt aattaggtgt attaactgtc aaaagccact gtgtcctgaa 360

atgcatggag atacacctac attgcatgaa tatatgttag atttgcaacc agagacaact 420

gatctctacg gttatggtca attaaatgac agctcagagg aggaggatga aatagatggt 480

ccagctggac aagcagaacc ggacagagcc cattacaata ttgtaacctt ttgttgcaag 540

tgtgactcta cgcttcggtt gtgcgtacaa agcacacacg tagacattcg tactttggaa 600

gacctgttaa tgggcacact aggaattgtg tgccccatct gttctcagaa accaaagctt 660

gagaaggagc agcgaatcct ggtcttcgac ttgggtggtg gcactttcga cgtttccctg 720

ctggagatcg gcgagggtgt ggttgaggtc cgtgccactt cgggtgacaa ccacctcggc 780

ggcgacgact gggaccagcg ggtcgtcgat tggctggtgg acaagttcaa gggcaccagc 840

ggcatcgatc tgaccaagga caagatggcg atgcagcggc tgcgggaagc cgccgagaag 900

gcaaagatcg agctgagttc gagtcagtcc acctcgatca acctgcccta catcaccgtc 960

gacgccgaca agaacccgtt gttcttagac gagcagctga cccgcgcgga gttccaacgg 1020

atcactcagg acctgctgga ccgcactcgc aagccgttcc agtcggtgat cgctgacacc 1080

ggcatttcgg tgtcggagat cgatcacgtt gtgctcgtgg gtggttcgac ccggatgcca 1140

gcggtgaccg atctggtcaa ggaactcacc ggcggcaagg aaccaaacaa gggcgtcaac 1200

ccagatgagg ttgtcgcggt gggagccgct ctgcaggccg gcgtcctcaa gggcgaggtg 1260

aaagacgttc tgctgcttga tgttaccccg taa 1293

<210>2

<211>430

<212>PRT

<213>Homo sapiens

<400>2

Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro

1 5 10 15

Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp

20 25 30

Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu

35 40 45

Val Gly Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly

50 55 60

Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile

65 70 75 80

Ser Glu Tyr Arg His Tyr Arg Tyr Ser Leu Tyr Gly Thr Thr Leu Glu

85 90 95

Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn

100 105 110

Cys Gln Lys Pro Leu Cys Pro Glu Met His Gly Asp Thr Pro Thr Leu

115 120 125

His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Gly

130 135 140

Tyr GlyGln Leu Asn Asp Ser Ser Glu Glu Glu Asp Glu Ile Asp Gly

145 150 155 160

Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr

165 170 175

Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr

180 185 190

His Val Asp Ile Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly

195 200 205

Ile Val Cys Pro Ile Cys Ser Gln Lys Pro Lys Leu Glu Lys Glu Gln

210 215 220

Arg Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser Leu

225 230 235 240

Leu Glu Ile Gly Glu Gly Val Val Glu Val Arg Ala Thr Ser Gly Asp

245 250 255

Asn His Leu Gly Gly Asp Asp Trp Asp Gln Arg Val Val Asp Trp Leu

260 265 270

Val Asp Lys Phe Lys Gly Thr Ser Gly Ile Asp Leu Thr Lys Asp Lys

275 280 285

Met Ala Met Gln Arg Leu Arg Glu Ala Ala Glu Lys Ala Lys Ile Glu

290 295 300

Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn Leu Pro Tyr Ile Thr Val

305 310 315 320

Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp Glu Gln Leu Thr Arg Ala

325 330 335

Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu Asp Arg Thr Arg Lys Pro

340 345 350

Phe Gln Ser Val Ile Ala Asp Thr Gly Ile Ser Val Ser Glu Ile Asp

355 360 365

His Val Val Leu Val Gly Gly Ser Thr Arg Met Pro Ala Val Thr Asp

370 375 380

Leu Val Lys Glu Leu Thr Gly Gly Lys Glu Pro Asn Lys Gly Val Asn

385 390 395 400

Pro Asp Glu Val Val Ala Val Gly Ala Ala Leu Gln Ala Gly Val Leu

405 410 415

Lys Gly Glu Val Lys Asp Val Leu Leu Leu Asp Val Thr Pro

420 425 430

Claims

1, a kind of recombinant protein vaccine, this recombinant protein vaccine be by the aminoacid sequence of ATP-binding site 161-370 amino acids sequence, HPV 16 E6 albumen 1-120 position in the hsp70 albumen and E7 albumen altogether 98 aminoacid sequences be formed by connecting, wherein the leucine with the 50th in E6 albumen is modified to glycine, cysteine that E7 is proteic the 24th and 26 glutamic acid be modified to glycine respectively.

2,, it is characterized in that being the aminoacid sequence shown in the SEQ ID NO:2 according to the described recombinant protein vaccine of claim 1.

3, according to the described recombinant protein vaccine of claim 1, it is characterized in that: HPV 16 E6 albumen is positioned at the aminoterminal of this recombiant protein, and hsp70 albumen is positioned at the c-terminus of this recombiant protein.

4, the nucleotide sequence of any recombinant protein vaccine of coding claim 1～3.

5,, it is characterized in that being the nucleotide sequence shown in the SEQ ID NO:1 according to the described nucleotide sequence of claim 4.

6, the expression vector that contains any described nucleotide sequence of claim 4～5.

7, the host cell that contains the described expression vector of claim 6.

8, any described recombinant protein vaccine of claim 1～3 treats and/or prevents disease relevant with the human papillomavirus and the purposes in the tumour medicine in preparation.

9, any described nucleotides sequence of claim 4～5 is listed in preparation and treats and/or prevents disease relevant with the human papillomavirus and the purposes in the tumour medicine.